

A new study to evaluate the effect of secukinumab in patients suffering from new-onset moderate to severe plaque psoriasis as early Intervention compared to standard treatment with narrow-band UVB phototherapy (StepIn)

Date: 19-SEP-2017

Dear Dr ,

When it comes to therapeutic options for treatment naïve patients with new onset plaque psoriasis, we usually initiate treatment with biologics only when topical agents, phototherapy and conventional systemic treatments have proved inadequate, even in patients with moderate to severe disease. We frequently find that once this therapy is discontinued, the patient's psoriatic skin lesions tend to recur, usually at the same sites that were previous affected.

I am currently working on the above study that is determining whether early intervention with a biologic secukinumab in this patient population is superior to treatment with narrow-band UVB in prolonging symptom-free periods, by preventing reactivation of old lesions or ultimately totally hindering the occurrence of new lesions.

This study is ongoing at Guy's Hospital. Any patients with new onset, moderate to severe plaque psoriasis that you have seen recently, or will be seen in your practice, and referred to my clinic for specialised treatment as per standard routine care may now be eligible for this trial. Potential patients referred may be screened for this trial at the clinic site.

If your patients are enrolled into the trial, I will inform you in writing.

Thank you for your cooperation.

Sincerely,

Dr Andrew Pink

Consultant Dermatologist

Louise Griffiths, Clinical Research Nurse, 07717 697 435